Last reviewed · How we verify
NCT04520906
To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
NA trial testing microwave ablation in Hepatocellular Carcinoma in 61 participants. Terminated before completion.
6 April 2022
Quick facts
| Lead sponsor | Suzhou Hengruihongyuan Medical Technology Co. LTD |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 61 |
| Start date | 17 December 2020 |
| Primary completion | 6 April 2022 |
| Estimated completion | 1 April 2023 |
| Sites | 13 locations across China |
Drugs / interventions tested
- microwave ablation
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Suzhou Hengruihongyuan Medical Technology Co. LTD
Who can join
Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Through the implementation of prospective, multi-center, single-group target value research to verify the safety and effectiveness of the microwave ablation treatment system for the ablation treatment of primary liver cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04520906
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of microwave ablation
Trials testing the same drug.
- NCT06537505 — A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors · Phase 2 · not yet recruiting
- NCT05477251 — Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodule · NA · not yet recruiting
- NCT04626986 — Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor · NA · unknown
- NCT03769129 — Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC · NA · recruiting
- NCT03286413 — Comparison of Microwave Ablation With Cryoablation for Breast Tumor · NA · unknown
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Suzhou Hengruihongyuan Medical Technology Co. LTD trials
Trials by the same sponsor.
- NCT07068438 — Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease · NA · recruiting
- NCT07053618 — Interventional Left Ventricular Assist System for PCI in CHIP Patients · NA · recruiting
- NCT05899478 — Suture-mediated Closure System Following Endovascular Peripheral Arterial Procedures · NA · completed
- NCT05719688 — Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke · NA · completed
- NCT05058482 — Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04520906 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Hengruihongyuan Medical Technology Co. LTD
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04520906.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing